Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Protea Biosciences Group, Inc.. (11/10/16). "Press Release: Protea Appoints David Halverson as President". Morgantown, WV.

Organisation Organisation Protea Biosciences Group Inc.
  Group Protea Biosciences (Group)
Products Product analytical instrument
  Product 2 LAESI technology (Laser Ablation Electrospray Ionization technology)
Persons Person Halverson, David (Concept Life Sciences 201801– US Head of Sales before Protea Bio + MPI Research + Huntingdon LS + PPD)
  Person 2 Turner, Stephen (Steve) (Protea Biosciences 201002 CEO)

Formerly The Company’s Vice President & Chief Business Officer

Protea Biosciences Group, Inc., (OTCQB:PRGB) announced today that the Company has appointed David Halverson as its President.

“We are pleased to announce the selection of David Halverson as President of Protea Biosciences,” stated Steve Turner, Protea’s Chairman & CEO. He added, “David has led the successful development of our proprietary molecular information services business. He is building a strong and growing customer base, which now includes major pharmaceutical and biotechnology companies; he is ideally suited to manage our business operations, as we position Protea to meet and lead the global demand for better molecular information, for improved pharmaceutical development.”

David Halverson commented, “I am honored to be appointed to the position of President, as we continue to grow the company and add amazing new capabilities to our expanding portfolio of proprietary Metabolic, Proteomic, Biopharmaceutical, and Mass Spec Imaging workflows. I have the highest confidence in our Company achieving the leadership position in the new molecular information services industry.”

Prior to his appointment as President, Halverson served as Protea’s Vice President and Chief Business Officer. Before joining Protea, Halverson was employed by Huntingdon Life Sciences in various capacities, including Head of European and US Sales. He has over 20 years of management experience in the pharmaceutical services industry, including serving as a Director of Sales for PPD Discovery and the Quintiles Preclinical Groups.

About Protea Biosciences

Protea Biosciences Group, Inc. (OTCQB:PRGB) is a leading molecular information company providing proprietary bio-analytical technology to the pharmaceutical and life science industries. "Molecular information" refers to the generation and bioinformatic processing of very large data sets, obtained by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biomolecules which are the byproducts of all living cells and life forms.

Protea is a registered trademark of Protea Biosciences Group, Inc.

For more Information:

Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA
Phone: 304.292.2226
Fax: 304.606.3049

Record changed: 2016-12-23


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Protea Biosciences (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

» top